AZD1402 (Elarekibep) Shows Low Immunogenicity in Early Human Trials

Biologic drugs, while highly effective, can sometimes trigger an immune response known as immunogenicity, where the body produces antibodies or T-cells against the drug. This can reduce drug efficacy and lead to adverse reactions. For novel therapeutics like AZD1402 (Elarekibep), understanding its potential to provoke such a response is paramount for patient safety and drug development. This study specifically investigated the T-cell epitope profile and overall immunogenic potential of AZD1402 in both healthy individuals and patients already exposed to the drug.

The study revealed a favorable immunogenicity profile for AZD1402 (Elarekibep). In healthy volunteers, only 2% (1 out of 50) exhibited a transient, low-level T-cell response, which resolved without clinical symptoms. Among drug-exposed participants, anti-drug antibodies (ADAs) were detected in a mere 1.5% (2 out of 100) of individuals, with no evidence of neutralizing antibodies. No significant increases in pro-inflammatory cytokines were observed in either cohort, with p-values > 0.05 for all tested cytokines compared to placebo. > AZD1402 (Elarekibep) demonstrated a remarkably low immunogenic potential, with minimal T-cell activation and a very low incidence of anti-drug antibody formation across all tested doses and participant groups. This suggests a robust safety margin regarding immune-mediated adverse events, contrasting sharply with some biologics that show ADA rates as high as 20-30%.